Letter of Intent Submission Process Is Now Closed.
The Stand Up To Cancer Innovative Research Grants program has been established in honor of the late Judah Folkman, M.D., to recognize him as one of the great innovators in cancer research. Dr. Folkman was internationally renowned as a pioneer in the field of angiogenesis research. In addition to his brilliant and distinguished cancer research career, Dr. Folkman was highly regarded by the cancer community as a supportive mentor, a dedicated teacher, and esteemed colleague.
An active member of the American Association for Cancer Research since 1990, Dr. Folkman was an early contributor to the SU2C project. He also served as an associate editor of two AACR journals, was the 1985 recipient of the AACR G.H.A. Clowes Memorial Award, and served as a trustee of the AACR Foundation for the Prevention and Cure of Cancer. Through his work with the AACR and through leadership and advisory positions with a host of prestigious scientific institutions and organizations, Dr. Folkman helped to define the field of cancer and biomedical research.
Program Mission Statement
The SU2C Innovative Research Grants are an effort to support the next generation of extraordinary leaders in their quest to conquer cancer. These grants will provide substantial funding to scientists whose novel, high-risk, high-reward cancer research proposals have significant potential for translational application, and hold great promise for advancing SU2C's overarching goal of improving and saving the lives of patients. It is the hope that ideas for new Stand Up To Cancer Dream Teams will emerge from these Innovative Research Grants, and this criterion will be given a high priority in the evaluation of the Letters of Intent.
To reflect the commitment of SU2C to funding novel approaches, research projects that are already being supported by the National Institutes of Health (NIH) R01 grants or the equivalent will not be accepted.
These grants will provide three years of funding of up to $750,000 over the grant term to support direct research expenses, depending upon project requirements.
LETTER OF INTENT SUBMISSION DEADLINE
November 15, 2010, at 12:00 p.m. ET
(for those invited to apply based on the Letter of Intent)
January 31, 2011
START OF GRANT TERM
May 1, 2011
Applicant Eligibility Criteria
Tenure-track, independent investigators who have completed their training no more than seven years prior to the start of the grant term are eligible to submit a Letter of Intent. That is, the applicant's first independent position must have started on or after May 2, 2004, and his or her current position must be tenure-track. Postdoctoral fellows, clinical research fellows, or any other researchers-in-training who are working under the direction of a scientific mentor are not eligible to apply.
For institutions that do not follow the traditional tenure system, such as non-academic, non-profit research institutions, tenure-track can be interpreted as, "a stated commitment from the institution of defined space that the applicant controls independent of other staff and defined money over a number of years to support the applicant's research. The nature of the applicant's appointment at the institution in terms of years and salary support must be independent of this or any other grant."
Applicants must have acquired a medical or other doctoral degree.
Applicants must be affiliated with an academic, medical, or research institution within the United States. There are no citizenship or residency status restrictions.
Employees or subcontractors of a government institution or for-profit industry are not eligible to apply as Principal Investigators, but may be listed as collaborators. No grant funds may be directed to collaborators working within government institutions or for-profit industry.
Individuals serving as Dream Team Leaders or Principals are not eligible.
Candidates with questions about their eligibility are encouraged to contact the AACR's SU2C Grants Office at SU2C@aacr.org prior to submitting a Letter of Intent. Applicants may be asked to submit letters from past and/or present employer(s) to assist in confirming eligibility.
Letter of Intent Submission Process
Letters of Intent (limited to two pages) must describe the proposed cancer research project and include the Specific Aims, Rationale and Approach, Novelty and Innovation, and Potential for Translational Application and Patient Benefit. Relevant references must be attached and are limited to one page.
Letters of Intent must be accompanied by:
- a scientific abstract, limited to 3,000 characters, providing a clear, concise overview of the proposed cancer research project;
- the CV and publication history of the Applicant; and
- a Letter of Commitment from the Applicant's department head, dean, or other senior member of the institution. The letter must confirm that the applicant has completed training on or after May 2, 2004, and currently holds an independent, tenure-track position; critically evaluate the scientific merit and novelty of the proposed research, the scientific independence demonstrated by the applicant in previous work, and the dedication of the applicant to cancer research; and explain the candidate's relationship with the institution and the nature and extent of support for the proposed research available from the institution, including laboratory space and financial and other resources. For clarification on "tenure-track" for non-tenure institutions, please see page four of the Program Guidelines and Submission Instructions.
Only one Letter of Intent per investigator will be accepted. A limited number of applicants whose Letters of Intent are deemed most meritorious will be invited to submit full research proposals and compete for the available grants.
Program Guidelines and Submission Instructions
Letters of Intent had to be completed online using the proposalCENTRAL website. Program Guidelines and Submission Instructions are available below and on the proposalCENTRAL website.
Program Guidelines and Submission Instructions (Adobe Acrobat Reader required)
Telephone: (267) 765-1049
Fax: (267) 765-1072
Updated: Nov. 15, 2010